<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434394</url>
  </required_header>
  <id_info>
    <org_study_id>9thShanghai</org_study_id>
    <secondary_id>10DZ1951300</secondary_id>
    <nct_id>NCT01434394</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer</brief_title>
  <acronym>EAGLE</acronym>
  <official_title>Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EGFR is a potential target for new anticancer therapy in head and neck squamous cell&#xD;
      carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the&#xD;
      stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced&#xD;
      apoptosis, and reduced angiogenesis, invasiveness and metastases. The study hypothesis is&#xD;
      that neo-adjuvant Erbitux-based chemotherapy followed by surgery and radiotherapy for locally&#xD;
      advanced oral/oropharyngeal cancer could benefit the patients on prognosis. The endpoints of&#xD;
      this study are the pathological complete response after neo-adjuvant Erbitux-based&#xD;
      chemotherapy followed by surgery and radiotherapy, the survival rate, and the safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study is the pathological complete response after neo-adjuvant&#xD;
      Erbitux-based chemotherapy followed by surgery and radiotherapy. The second endpoint of this&#xD;
      study is the disease free survival rates (1, 2, 3, 5 years), locoregional control rates (1,&#xD;
      3, 5 years), overall survival rate (3, 5 years), and the safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To evaluate pathological Complete Response (pCR) after neo-adjuvant Erbitux-based chemotherapy followed by surgery and radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease Free Survival (DFS) rates (1, 2, 3, 5 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Control rates</measure>
    <time_frame>5 years</time_frame>
    <description>Locoregional Control rates (LCR) (1, 3, 5 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival (OS) rate (3, 5 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>All Adverse Events(AEs),including Serious Adverse Events(SAEs), Exposure of All study drugs &amp; radiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <condition>Oral Cancer</condition>
  <condition>Oropharyngeal Carcinoma</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant Erbitux-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery and radiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgery and post-operative radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neo-adjuvant Erbitux-based chemotherapy</intervention_name>
    <description>Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency &amp; treatment mode: Weekly Duration: 6 weeks&#xD;
Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency &amp; treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)&#xD;
Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency &amp; treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)</description>
    <arm_group_label>Neo-adjuvant Erbitux-based chemotherapy</arm_group_label>
    <other_name>Followed by surgery and radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent prior to any study activities&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Histological/cytological and iconography confirmed squamous-celled oral/oropharyngeal&#xD;
             cancer&#xD;
&#xD;
          -  Stage Ⅲ/Ⅳa (T1-2, N1-2, M0 or T3-4, N0-2, M0, AJCC 2010), operable disease&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥70&#xD;
&#xD;
          -  Adequate hematologic function: Neutrophils ≥1,500/mm^3, WBC &gt;4,000/mm^3, Hb &gt; 10 g/dL,&#xD;
             platelet count &gt;100,000/mm^3&#xD;
&#xD;
          -  Hepatic function: ALAT/ASAT &lt;2.5 times the upper limit of normal (ULN), bilirubin &lt;1.5&#xD;
             x ULN&#xD;
&#xD;
          -  Renal function: serum creatinine &lt;1.5 x ULN&#xD;
&#xD;
          -  Life expectancy ≥6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of distant metastatic disease and other oropharyngeal cancers&#xD;
&#xD;
          -  Surgical procedure of the primary tumor or lymph nodes (except diagnostic biopsy)&#xD;
             before study treatment&#xD;
&#xD;
          -  Previous radiotherapy for the primary tumor or lymph nodes&#xD;
&#xD;
          -  Previous exposure to epidermal growth factor-targeted therapy&#xD;
&#xD;
          -  Prior chemotherapy or immunotherapy for the primary tumor&#xD;
&#xD;
          -  Other previous malignancy within 5 years, except non-melanoma skin cancer or&#xD;
             pre-invasive carcinoma of the cervix&#xD;
&#xD;
          -  Any investigational agent prior to the 1st study medication&#xD;
&#xD;
          -  Participation in another clinical study within the 30 days prior to Inclusion in this&#xD;
             study.&#xD;
&#xD;
          -  Peripheral neuropathy &gt;grade 1&#xD;
&#xD;
          -  Known grade 3 or 4 allergic reaction to any of the study treatment&#xD;
&#xD;
          -  History of severe pulmonary or cardiac disease&#xD;
&#xD;
          -  Creatinine Clearance &lt;30 ml/min&#xD;
&#xD;
          -  Know drug abuse /alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Medical or psychiatric illness, which in the investigators' opinions, would not permit&#xD;
             the subject to complete or fully and completely understand the risks and potential&#xD;
             complications of the study&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy or hormone therapy not indicated in the&#xD;
             study protocol&#xD;
&#xD;
          -  Pregnancy (confirmed by serum or urine β-HCG) or lactation period&#xD;
&#xD;
          -  Severe cardiac disease such as heart failure, clinical relevant cardiac dysrhythmias,&#xD;
             coronary artery disease or myocardial infarction within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-ping Zhang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oral and Maxillofacial Surger, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Lai-ping Zhong</investigator_full_name>
    <investigator_title>Ninth People's Hospital, School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Oral cancer</keyword>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Targeted chemotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

